Date of Original Version
EpiVax, Inc., is an early-stage informatics and immunology biotechnology company in Providence, Rhode Island. It applies computational tools to harness immunity in three major areas: immunomodulation, biotherapeutic immunogenicity risk assessment and de-risking, and vaccine development. Immunotherapy, bio-better and vaccine candidates under development at EpiVax promise to improve the health outcomes of millions of people affected by devastating immune-related diseases.
Moise, L., Marcello, A., Tassone, R., Cousens, L., Martin, W., & De Groot, A. S. (2013). Building Better Biotherapeutics and Vaccines by Design: EpiVax, Inc., Immunology Company. Rhode Island Medical Journal, 1(96),19-21.